Home / Intelligence / Scientific Publications / Comparative Comorbidity Burden Among Patients with Prader-Willi Syndrome: A Population-Level Cohort Survey
Prader-Willi syndrome (PWS) is a rare, complex multi-system genetic disorder characterized by hyperphagia and abnormal food-related behaviors that contribute to severe morbidity and early mortality and to a significant burden on patients and caregivers. The hyperphagia seen in people with PWS can result in significant obesity. This study assessed rates of comorbidities associated with obesity, including type II diabetes (T2D), cardiovascular disease (CVD), and sleep apnea (SA) in a large US PWS vs. a non-PWS cohort.
Authors
Diane Stafford, Justin Li, David Yin, Michael Yeh, Shawn Czado, Sina Aghsaei, Marissa Suh, Kevin Francis, Shawn McCandless
Journal
Journal of the Endocrine Society; Volume 4; Issue Supplement_1; April-May 2020
Related Intelligence
Webinars
The Future of Patient Finding
November 13, 2024 | 1:00 – 1:45 PM ET
Two additional sessions will be offered: November 14 – 16:00 – 16:45 (UTC +8:00) – Asia/Shanghai November 14 – 15:00 – 15:45 CET – Europe/Berlin Patient finding is more than a buzzword. Ready to challenge the status quo? With more data, advancements in AIML and greater access to insights, it is not surprising that patient […]
Sign Up Now
White Papers
Moving the Needle: Lessons from the 2023 Launch Class
The 2023 launch class exceeded Trinity Life Sciences’ expectations with only 50% underperforming their pre-launch first year forecasts while 39% overperformed, indicating an improvement from prior years (54% and 35%, respectively, for 2020–2023). This was driven by notable improvements in “Specialty and Large Market” products (36% overperformed vs. 18% average in years prior) and First Launch Companies (33% overperformed vs. 20% in years prior). The needle is moving.
Read More
White Papers
2023 NRDL Pricing Implementation and Market Access Outcomes Update
The National Reimbursement Drug List (NRDL) negotiations are expected to conclude by November 2024, with pricing outcomes gradually being revealed starting in January 2025. The Trinity Life Sciences team has reviewed the 2023 NRDL inclusion and pricing results, drawing some key learnings.
Read More